Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

You also don't need a substantial amount of money on hand to invest. Here are three prominent healthcare companies you can ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

Itching is often the most debilitating cutaneous symptom of CKD and ESRD. Experts recommend a stepwise treatment approach ...

Princeton: Bristol Myers Squibb and Bain Capital have announced the formation of a new independent biopharmaceutical company, ...

Indiana saw the second biggest small business growth in July, while President Trump is expected to impose tariffs on medicine ...